Generic
Zoledronic Acid [For hypercalcemia]
10 brands available in the market
At a glance
Zoledronic Acid is indicated in hypercalcaemia of malignancy, bone metastases associated with solid tumours, osteolytic lesions associated with multiple myeloma, corticosteroid-induced osteoporosis, and more.
Description
Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption.
Indications
- Hypercalcaemia of malignancy
- Bone metastases associated with solid tumours
- Osteolytic lesions associated with multiple myeloma
- Corticosteroid-induced osteoporosis
- Increase bone mass in men with osteoporosis
- Osteoporosis in postmenopausal women
- Paget's disease of bone
- Prophylaxis of postmenopausal osteoporosis
Therapeutic class
Bisphosphonate preparations
Pharmacological class
Bisphosphonate
Pharmacology
Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption.
Mechanism of action
Inhibits osteoclast activity, reducing bone resorption and strengthening bones.
Dosage
Adult Dose (IV):
- Hypercalcemia of malignancy: 4 mg as a single dose by infusion over at least 15 minutes
- Multiple myeloma and bone metastases of solid tumors: 4 mg infusion over at least 15 minutes every 3-4 weeks
Renal Impairment: CrCl >60 mL/min: 4 mg; CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3 mg; CrCl <30: not recommended
Administration
- Administered by a doctor or nurse as an IV infusion
- Duration of infusion must not be less than 15 minutes
- Must not be mixed with calcium or other divalent cation-containing infusion solutions
Missed dose
If you miss a dose, consult your doctor.
Side effects
Common Side Effects:
- Headache
- Nausea
- Anorexia
- Fatigue
- Osteonecrosis of jaw
- Anemia
- Bone pain
- Constipation
- Fever
- Vomiting
- Flu-like syndrome
- Hypocalcemia
- Myalgia
- Arthralgia
Precautions & warnings
- Patients must be appropriately hydrated prior to administration
- Serum levels of calcium, phosphate, magnesium and potassium, as well as serum creatinine should be carefully monitored
- If hypocalcemia, hypophosphatemia or hypomagnesemia occurs, short-term supplemental therapy may be necessary
- Careful renal function monitoring should be considered
Contraindications
- Hypersensitivity to the active substance or to any of the excipients or to any bisphosphonates
- Hypocalcaemia
- Severe renal impairment (Creatinine clearance <30 ml/min)
- Current or recent uveitis, or a history of bisphosphonate-associated uveitis
- Pregnancy and lactation
Drug interactions
- Aminoglycosides and loop diuretics: increased risk of hypocalcaemia
- Nephrotoxic agents: increased risk renal dysfunction
- Thalidomide: increased risk of renal dysfunction in multiple myeloma patients
Food interactions
Caution is advised when consuming alcohol with Zoledronic Acid.
Use in pregnancy
Use in Pregnancy: Unsafe; definite evidence of risk to the developing baby; consult your doctor.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Use in lactation
Use in Lactation: Probably unsafe; may pass into breast milk and harm the baby; consult your doctor.
Pediatric use
Not recommended for use in children and adolescents below 18 years of age
Geriatric use
Caution required in elderly patients
Renal / hepatic impairment
Renal Impairment: CrCl >60 mL/min: 4 mg; CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3 mg; CrCl <30: not recommended
Hepatic Impairment: Limited information
Overdose effects
Symptoms: Hypocalcemia, hypophosphatemia, and hypomagnesemia.
Treatment: Correct by intravenous administration of calcium gluconate, potassium or sodium phosphate and magnesium sulfate.
Storage conditions
Store below 30°C prior to opening. Protect from moisture and light. Keep out of the reach and sight of children.